ProPhase Labs Updates Shareholders on Convertible Debt Conversions, Capital Structure, and Asset Value

ProPhase Labs, Inc. (OTC: PRPH) issued a detailed shareholder update on January 5, 2026, addressing recent stock price volatility, capital structure changes, and the value of the company’s core assets. Management explained that short‑term technical factors — including the accelerated conversion and resale of a large portion of outstanding convertible debt, a recent 1‑for‑10 reverse stock split, and the company’s transition from Nasdaq to the OTC market — have driven trading fluctuations, not changes in the business fundamentals. More than $3.3 million of the original $3.8 million convertible debt principal has now been converted into equity, reducing overall debt and increasing shareholders’ equity, while leaving less than $500,000 unconverted. These conversions were executed at a floor price near $0.76 per share, which is significantly above the company’s current trading price, thereby lessening future conversion‑related selling pressure. ProPhase Labs emphasized that although these events increased the number of shares outstanding, they also strengthened the balance sheet and did not change the underlying value of its operating subsidiaries or assets. CEO Ted Karkus underscored the distinction between share count mechanics and intrinsic enterprise value, citing the company’s key initiatives like the Crown Medical receivables recovery, the BE‑Smart Esophageal Cancer diagnostic test, and Nebula Genomics/DNA Complete as evidence of significant underlying value. Looking ahead, the company continues to focus on stabilizing its capital structure, advancing financing initiatives, and progressing core operations, while maintaining transparent communication with shareholders. #ProPhaseLabs #ConvertibleDebt #CapitalStructure #BiotechNews #SlimScan #GrowthStocks #CANSLIM